At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
RBM-007 Injectable Solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1/2 Open Label, Dose-escalation Study of the Safety and OcUlar Tolerability of a Single Intravitreal Injection of RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (SUSHI)
In Brief
A Phase 2 clinical trial evaluating RBM-007 Injectable Solution for Age-related Macular Degeneration. Completed, enrolled 9 participants across 4 sites.
Detailed Summary
This is an open label, non-controlled, dose-escalating study assessing the safety, tolerability, and bioactivity of a single intravitreal (i.vt.) injection of RBM-007 in approximately nine subjects with exudative age-related macular degeneration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-related Macular Degeneration
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartAug 2018
Primary CompletionJun 2019
TodayJul 2026
First PostedAug 16, 2018
Enrollment StartAug 29, 2018
Primary CompletionJun 26, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.9 years ago
Interventions
RBM-007 Injectable Solutiondrug
(No additional description)